There are two types of glass bottles, one is medium borosilicate glass bottle and the other is low borosilicate glass bottle. my country does not yet have the large-scale mass production capacity of medium borosilicate glass bottles. The medicinal glass bottles that my country can produce are mainly low borosilicate glass bottles.
Data shows that vaccine glass bottles are not ordinary glass bottles, but medium borosilicate glass bottles. They are far superior to soda-lime glass and low borosilicate glass in terms of water resistance, acid and alkali resistance, freezing resistance, thermal stability, and filling speed. They are not easy to cause “flaking” caused by drug immersion and erosion. Compared with other pharmaceutical glass bottles, they have incomparable superiority in drug quality is a recognized pharmaceutical packaging material.
Due to the high threshold and high technical requirements of medium boron pharmaceutical glass, the country currently mainly relies on imports. However, with strong domestic and foreign market demand, domestic companies are expected to gain new opportunities, forcing domestic companies to gradually engage in the production of neutral borosilicate pharmaceutical glass, upgrade and replace low borosilicate or soda-lime pharmaceutical glass, and promote the development of the domestic neutral pharmaceutical glass industry.
As China's policies and the concept of a healthy China advance, pharmaceutical packaging is constantly being upgraded, which will greatly promote the upgrade of low-borosilicon glass to medium-borosilicon glass. It predicts that in the next 5~10 years, 30%-40% of China's 300,000 tons of medicinal glass will be upgraded from low borosilicate glass to medium borosilicate glass.
On Friday, affected by the vaccine bottle “emergency”, A-share Zhengchuan Co., Ltd. closed its daily limit after opening high; Shandong Pharmaceutical Glass and Qibin Group rose by more than 8%, and these three companies all had a clear layout of boron glass
On March 10, Zhengchuan Co., Ltd. disclosed its "2020 Annual Report", and the company's performance declined again. Among them, revenue reached 501.9817 million yuan, a year-on-year decrease of 3.67%; net profit attributable to shareholders of the listed company was 53.0505 million yuan, a year-on-year decrease of 13.11%. In the annual report, Zhengchuan Co., Ltd. introduced that the company is engaged in the research and development, production and sales of medicinal packaging materials such as medicinal glass controlled bottles. It is now one of the enterprises in the pharmaceutical glass controlled bottle sub-sector in the industry.
But in recent years. Data shows that in 2013—2020, the company's revenue ranged from 400 million to 500 million yuan; in terms of net profit, since 2018, its attributable net profit has been negative for three consecutive years due to rolling month-on-month growth. Just two days before the annual report was disclosed, on March 8, because the information disclosure was untrue and incomplete,
Pharmaceutical glass industry Shandong Pharmaceutical Glass is also actively developing the field of borosilicate pharmaceutical glass manufacturing. In February this year, Shandong Yaogu stated on the interactive platform that the company's annual output of medium borosilicate glass bottles is 250 million to 300 million units; at present, the defects of medium borosilicate glass tubes have improved, and the company has not introduced foreign kiln technology and equipment. The industry predicts that the company's new production capacity for neutral borosilicate glass molded products is expected to be put into production quickly; it is expected that a certain time will be needed for the concentrated breakthrough of neutral borosilicate glass control technology. Product structure optimization brought about by industry upgrades will continuously improve the company's profitability.
In addition, many companies plan to increase their investment in the field of neutral medicinal glass. For example, the "Announcement on Joint Investment in the Construction of Neutral Borosilicate Pharmaceutical Vitrin Tube Project and Related-Party Transactions" issued in May 2020 shows that the company plans to invest in the neutral borosilicate pharmaceutical glass project. The project is planned to be built in phases, with a construction scale of 3 kilns, 8 lines and 100 tons/day (kiln discharge volume) of neutral borosilicate pharmaceutical vitrin tubes As well as product deep processing, the total investment of the project is about 600 million yuan; Deli Co., Ltd. also stated on the interactive platform that the company communicates and explores in the field of related glass materials.
